BG64370B1 - Използване на 1-хидрокси-2-пиридон за лечение на кожни заболявания - Google Patents

Използване на 1-хидрокси-2-пиридон за лечение на кожни заболявания Download PDF

Info

Publication number: BG64370B1
Authority: BG; Bulgaria
Prior art keywords: hydroxy; pyridone; formula; use according; treatment
Prior art date: 1996-09-27

Application number

BG103261A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG103261A (en

Inventor

Manfred Bohn

Karl Kraemer

Astrid Markus

Original Assignee

Hoechst Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-27

Filing date

1999-03-17

Publication date

2004-12-30

1999-03-17 Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft

1999-09-30 Publication of BG103261A publication Critical patent/BG103261A/xx

2004-12-30 Publication of BG64370B1 publication Critical patent/BG64370B1/bg

Links

SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical compound ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 title claims description 9
208000017520 skin disease Diseases 0.000 title abstract description 3
150000001875 compounds Chemical class 0.000 claims abstract description 14
241000894006 Bacteria Species 0.000 claims abstract description 13
230000000699 topical effect Effects 0.000 claims abstract description 9
206010040872 skin infection Diseases 0.000 claims description 14
125000004432 carbon atom Chemical group C* 0.000 claims description 11
-1 chloro, bromo, methoxy Chemical group 0.000 claims description 9
230000003115 biocidal effect Effects 0.000 claims description 7
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 5
SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 5
229910052717 sulfur Inorganic materials 0.000 claims description 5
208000002874 Acne Vulgaris Diseases 0.000 claims description 4
241000588724 Escherichia coli Species 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
206010000496 acne Diseases 0.000 claims description 4
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
244000005700 microbiome Species 0.000 claims description 4
125000004434 sulfur atom Chemical group 0.000 claims description 4
241000588748 Klebsiella Species 0.000 claims description 3
241000295644 Staphylococcaceae Species 0.000 claims description 3
125000003118 aryl group Chemical group 0.000 claims description 3
244000052616 bacterial pathogen Species 0.000 claims description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
150000002430 hydrocarbons Chemical group 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
JSYOKKNLZSPUCV-UHFFFAOYSA-N 1-hydroxy-4-methyl-6-(2,4,4-trimethylcyclohexa-1,5-dien-1-yl)pyridin-2-one Chemical compound C1=CC(C)(C)CC(C)=C1C1=CC(C)=CC(=O)N1O JSYOKKNLZSPUCV-UHFFFAOYSA-N 0.000 claims description 2
241001465754 Metazoa Species 0.000 claims description 2
241000588769 Proteus <enterobacteria> Species 0.000 claims description 2
241000589516 Pseudomonas Species 0.000 claims description 2
235000010290 biphenyl Nutrition 0.000 claims description 2
239000004305 biphenyl Substances 0.000 claims description 2
125000001246 bromo group Chemical group Br* 0.000 claims description 2
125000001309 chloro group Chemical group Cl* 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
201000004700 rosacea Diseases 0.000 claims description 2
229930195734 saturated hydrocarbon Natural products 0.000 claims description 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
UDYUIWXQUBNDHC-UHFFFAOYSA-N 6-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-hydroxy-4-methylpyridin-2-one Chemical compound ON1C(=O)C=C(C)C=C1COC(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 UDYUIWXQUBNDHC-UHFFFAOYSA-N 0.000 claims 1
125000002619 bicyclic group Chemical group 0.000 claims 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
241000233866 Fungi Species 0.000 abstract description 5
230000001580 bacterial effect Effects 0.000 description 11
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 10
239000000203 mixture Substances 0.000 description 10
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
239000013543 active substance Substances 0.000 description 8
150000003839 salts Chemical class 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 5
229930182566 Gentamicin Natural products 0.000 description 5
241000191963 Staphylococcus epidermidis Species 0.000 description 5
229960002227 clindamycin Drugs 0.000 description 5
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 5
229960003276 erythromycin Drugs 0.000 description 5
229960002518 gentamicin Drugs 0.000 description 5
GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
229960003085 meticillin Drugs 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
241000191967 Staphylococcus aureus Species 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
231100000676 disease causative agent Toxicity 0.000 description 3
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 3
229960001699 ofloxacin Drugs 0.000 description 3
241000894007 species Species 0.000 description 3
238000012360 testing method Methods 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
235000001674 Agaricus brunnescens Nutrition 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
208000031888 Mycoses Diseases 0.000 description 2
206010034133 Pathogen resistance Diseases 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
229920001214 Polysorbate 60 Polymers 0.000 description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
241000589517 Pseudomonas aeruginosa Species 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
108010059993 Vancomycin Proteins 0.000 description 2
241001148470 aerobic bacillus Species 0.000 description 2
239000008272 agar Substances 0.000 description 2
238000002814 agar dilution Methods 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000002585 base Substances 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229960003165 vancomycin Drugs 0.000 description 2
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
NAMCVYZZXAXRBX-UHFFFAOYSA-N 1-hydroxy-4-methyl-6-[[4-[2-(trifluoromethyl)phenoxy]phenoxy]methyl]pyridin-2-one Chemical compound ON1C(C=C(C=C1COC1=CC=C(C=C1)OC1=C(C=CC=C1)C(F)(F)F)C)=O NAMCVYZZXAXRBX-UHFFFAOYSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
KSMVBYPXNKCPAJ-UHFFFAOYSA-N 4-Methylcyclohexylamine Chemical compound CC1CCC(N)CC1 KSMVBYPXNKCPAJ-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
RJQXTJLFIWVMTO-UHFFFAOYSA-N 6-[(2,6-dimethoxybenzoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound COC1=CC=CC(OC)=C1C(=O)NC1C(=O)N2C(C(O)=O)C(C)(C)SC21 RJQXTJLFIWVMTO-UHFFFAOYSA-N 0.000 description 1
NOMIBIVUURZCPM-UHFFFAOYSA-N 6-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-hydroxy-3,4-dimethylpyridin-2-one Chemical compound ON1C(=O)C(C)=C(C)C=C1COC(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 NOMIBIVUURZCPM-UHFFFAOYSA-N 0.000 description 1
MJQVWFQOPJBTIP-UHFFFAOYSA-N 6-[[4-[(2,4-dichlorophenyl)methyl]phenoxy]methyl]-1-hydroxy-3,4-dimethylpyridin-2-one Chemical compound ON1C(=O)C(C)=C(C)C=C1COC(C=C1)=CC=C1CC1=CC=C(Cl)C=C1Cl MJQVWFQOPJBTIP-UHFFFAOYSA-N 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
241000186427 Cutibacterium acnes Species 0.000 description 1
241000588697 Enterobacter cloacae Species 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
241000588915 Klebsiella aerogenes Species 0.000 description 1
241000588747 Klebsiella pneumoniae Species 0.000 description 1
101500021084 Locusta migratoria 5 kDa peptide Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
IRWYXHIHZOOIIZ-UHFFFAOYSA-N ON1C(C(=C(C=C1)C)C1C2CCC(C1)C2)=O Chemical compound ON1C(C(=C(C=C1)C)C1C2CCC(C1)C2)=O IRWYXHIHZOOIIZ-UHFFFAOYSA-N 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000186429 Propionibacterium Species 0.000 description 1
241000334216 Proteus sp. Species 0.000 description 1
241000588767 Proteus vulgaris Species 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
206010041925 Staphylococcal infections Diseases 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000001651 autotrophic effect Effects 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
229940018006 basil oil Drugs 0.000 description 1
239000010619 basil oil Substances 0.000 description 1
NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
229940049638 carbomer homopolymer type c Drugs 0.000 description 1
229940082484 carbomer-934 Drugs 0.000 description 1
229940043234 carbomer-940 Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001767 cationic compounds Chemical class 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000034303 cell budding Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
239000006071 cream Substances 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
LTYMSROWYAPPGB-UHFFFAOYSA-N diphenyl sulfide Chemical class C=1C=CC=CC=1SC1=CC=CC=C1 LTYMSROWYAPPGB-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
229940092559 enterobacter aerogenes Drugs 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
239000000499 gel Substances 0.000 description 1
229940074047 glyceryl cocoate Drugs 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229910001411 inorganic cation Inorganic materials 0.000 description 1
108010059345 keratinase Proteins 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
CRVGTESFCCXCTH-UHFFFAOYSA-N methyl diethanolamine Chemical compound OCCN(C)CCO CRVGTESFCCXCTH-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
229940100573 methylpropanediol Drugs 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
YWFWDNVOPHGWMX-UHFFFAOYSA-N n,n-dimethyldodecan-1-amine Chemical compound CCCCCCCCCCCCN(C)C YWFWDNVOPHGWMX-UHFFFAOYSA-N 0.000 description 1
WYZDCUGWXKHESN-UHFFFAOYSA-N n-benzyl-n-methyl-1-phenylmethanamine Chemical compound C=1C=CC=CC=1CN(C)CC1=CC=CC=C1 WYZDCUGWXKHESN-UHFFFAOYSA-N 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229940055019 propionibacterium acne Drugs 0.000 description 1
229940007042 proteus vulgaris Drugs 0.000 description 1
125000001453 quaternary ammonium group Chemical class 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940073455 tetraethylammonium hydroxide Drugs 0.000 description 1
LRGJRHZIDJQFCL-UHFFFAOYSA-M tetraethylazanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)CC LRGJRHZIDJQFCL-UHFFFAOYSA-M 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
241001148471 unidentified anaerobic bacterium Species 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
150000003754 zirconium Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BG103261A 1996-09-27 1999-03-17 Използване на 1-хидрокси-2-пиридон за лечение на кожни заболявания BG64370B1 (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19639817A DE19639817A1 (de)	1996-09-27	1996-09-27	Verwendung von 1-Hydroxy-2-pyridonen zur Behandlung von Hautinfektionen

Publications (2)

Publication Number	Publication Date
BG103261A BG103261A (en)	1999-09-30
BG64370B1 true BG64370B1 (bg)	2004-12-30

Family

ID=7807117

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103261A BG64370B1 (bg)	1996-09-27	1999-03-17	Използване на 1-хидрокси-2-пиридон за лечение на кожни заболявания

Country Status (32)

Country	Link
US (1)	US6469033B1 (id)
EP (1)	EP0928193B1 (id)
JP (1)	JP4203125B2 (id)
KR (1)	KR100457851B1 (id)
CN (1)	CN1141096C (id)
AR (1)	AR008859A1 (id)
AT (1)	ATE218862T1 (id)
AU (1)	AU717333B2 (id)
BG (1)	BG64370B1 (id)
BR (1)	BR9712141A (id)
CA (1)	CA2267309C (id)
CZ (1)	CZ290701B6 (id)
DE (2)	DE19639817A1 (id)
DK (1)	DK0928193T3 (id)
ES (1)	ES2178761T3 (id)
HU (1)	HU226911B1 (id)
ID (1)	ID21948A (id)
IL (1)	IL129144A0 (id)
MA (1)	MA24332A1 (id)
MY (1)	MY117381A (id)
NO (1)	NO322072B1 (id)
NZ (1)	NZ334848A (id)
OA (1)	OA11027A (id)
PL (1)	PL190298B1 (id)
PT (1)	PT928193E (id)
RU (1)	RU2203059C2 (id)
TR (1)	TR199900661T2 (id)
TW (1)	TW531418B (id)
UA (1)	UA56192C2 (id)
WO (1)	WO1998013043A1 (id)
YU (1)	YU49494B (id)
ZA (1)	ZA978639B (id)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040039030A1 (en) *	1996-09-27	2004-02-26	Hoechst Akeengesellschaft	Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
DE19639816A1 (de) *	1996-09-27	1998-04-02	Hoechst Ag	Antimykotische Mittel mit hoher Wirkstofffreisetzung
AU2003218507A1 (en) *	2002-04-04	2003-10-20	Medicis Pharmaceutical Corporation	Methods for treating rosacea with pyridones
ITMI20022447A1 (it) *	2002-11-19	2004-05-20	Carlo Ghisalberti	Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate.
US20050095215A1 (en) *	2003-11-03	2005-05-05	Popp Karl F.	Antimicrobial shampoo compositions
WO2005110988A1 (en) *	2004-05-07	2005-11-24	Janssen Pharmaceutica, N.V.	Pyridone compounds as inhibitors of bacterial type iii protein secretion systems
DE102005001990A1 (de) *	2005-01-15	2006-07-20	Clariant Gmbh	Wässrige fungizide Zubereitungen
US20070071705A1 (en) *	2005-09-29	2007-03-29	De Oliveira Monica A M	Topical anti-microbial compositions
RU2317110C1 (ru) *	2006-11-07	2008-02-20	Общество с ограниченной ответственностью "Уралстинол Био"	Кожное антисептическое средство "септустин-антисепт"
AU2012302022A1 (en)	2011-08-29	2014-03-13	Ptc Therapeutics, Inc.	Antibacterial compounds and methods for use
HK1199693A1 (en)	2011-08-29	2015-07-17	Ptc Therapeutics, Inc.	Antibacterial compounds and methods for use
CN103360308A (zh) *	2012-03-28	2013-10-23	孙伟新	1,4-二羟基-6-甲基-2-吡啶酮类化合物及其制备方法和用途
DE102015219008A1 (de)	2015-10-01	2017-04-06	Beiersdorf Ag	Sonnenschutzmittel mit reduzierter Textilverfleckung durch 4-(tert.-Butyl)-4'-methoxydibenzoylmethan
DE102015219006A1 (de)	2015-10-01	2017-04-20	Beiersdorf Ag	Sonnenschutzmittel mit reduzierter Textilverfleckung durch Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine
DE102015219009A1 (de)	2015-10-01	2017-04-06	Beiersdorf Ag	Sonnenschutzmittel mit reduzierter Textilverfleckung durch Diethylamino Hydroxybenzoyl Hexyl Benzoate
DE102015219592A1 (de)	2015-10-09	2017-04-13	Beiersdorf Aktiengesellschaft	Sonnenschutzmittel mit stark reduzierter Textilverfleckung durch Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine
DE102015219591A1 (de)	2015-10-09	2017-04-13	Beiersdorf Aktiengesellschaft	Sonnenschutzmittel mit stark reduierter Textilverfleckung durch 4-(tert.-Butyl)-4 - methoxydibenzoylmethan

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR771187A (fr) *	1934-12-26	1934-10-02		Moule en caoutchouc pour conduites en ciment, armé ou non
US3968118A (en)	1968-08-31	1976-07-06	Hoechst Aktiengesellschaft	Process for the manufacture of 1-hydroxy-2-pyridones
US4185106A (en)	1972-07-11	1980-01-22	Hoechst Aktiengesellschaft	Pyridones as antidandruff agents
DE3140954A1 (de)	1981-10-15	1983-05-05	Hoechst Ag	"verwendung von 1-hydroxy-2-pyridonen zur prophylaxe und behandlung von akne"
JPS6169721A (ja)	1984-09-13	1986-04-10	Kao Corp	抗真菌組成物
GB8524508D0 (en)	1985-10-04	1985-11-06	Beecham Group Plc	Composition
DE3687458T2 (de)	1985-11-04	1993-07-29	Owen Galderma Lab Inc	Filmbildende arzneimitteltraeger zur verabreichung von arzneimitteln an naegeln
DE3544983A1 (de)	1985-12-19	1987-06-25	Hoechst Ag	Antimykotisch wirksamer nagellack
DE3779352D1 (de)	1986-04-18	1992-07-02	Hoechst Ag	1-hydroxy-2-pyridone, verfahren zu ihrer herstellung und arzneimittel, die sie enthalten, sowie bei der herstellung der 1-hydroxy-2-pyridone gebildete zwischenprodukte.
NL8601762A (nl)	1986-07-07	1988-02-01	Bouke Jan Lange	Werkwijze voor de reiniging en conditionering en eventuele medicinale behandeling van het haar en de hoofdhuid, een voor dit doel bruikbare tweefasen shampoo, alsmede een verpakking daarvoor.
US5641475A (en) *	1987-05-15	1997-06-24	Tristrata, Inc.	Antiodor, antimicrobial and preservative compositions and methods of using same
DE3720147A1 (de)	1987-06-16	1988-12-29	Hoechst Ag	Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung
LU86944A1 (fr)	1987-07-17	1989-03-08	Oreal	Composition a base de derives d'hydroxypyridone pour diminuer la chute des cheveux
LU86945A1 (fr) *	1987-07-17	1989-03-08	Oreal	Compositions pharmaceutiques et cosmetiques a base de pyridones et d'agents antibacteriens
DE3856315T2 (de)	1987-10-22	1999-10-14	The Procter & Gamble Co.	Chelatbildner enthaltende Lichtschutzmittel
HU202098B (en)	1988-08-05	1991-02-28	Istvan Laczko	Nail polish remover without aceton
DE3826914A1 (de)	1988-08-09	1990-02-15	Henkel Kgaa	Farbstabilisierung von antimikrobiellen zubereitungen
US5116603A (en)	1989-01-31	1992-05-26	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Oral antifungal preventative, and method of use
CA2008775C (en)	1989-02-24	1998-12-22	Alberto Ferro	Nail lacquer
JPH0623087B2 (ja)	1989-10-09	1994-03-30	花王株式会社	洗浄剤組成物
US5066484A (en)	1990-04-30	1991-11-19	Revlon, Inc.	Nail enamels containing glyceryl, glycol or citrate esters
HU219480B (hu)	1991-05-23	2001-04-28	Novartis Ag.	Eljárás gombás körömmegbetegségek ellen helyileg alkalmazható, allil-amin-származékot tartalmazó gyógyászati készítmények előállítására
FR2685638A1 (fr)	1991-12-31	1993-07-02	Biorga Sa Laboratoires	Compositions pour l'usage cosmetique et/ou dermatologique, comprenant une association de pyrithione zinc, de piroctone olamine, et d'un derive de collagene et d'acide gras.
FR2685867B1 (fr)	1992-01-07	1995-06-09	Thorel Jean	Compositions contre la desquamation de l'epiderme et du cuir chevelu.
DE4212105A1 (de)	1992-04-10	1993-10-14	Roehm Pharma Gmbh	Nagellack zur Behandlung von Onychomykosen
FR2694694B1 (fr)	1992-08-13	1994-10-28	Thorel Jean Noel	Composition active pour le traitement du psoriasis, notamment le psoriasis du cuir chevelu.
KR950702819A (ko)	1992-09-08	1995-08-23	제이코버스 코넬리스 레이서	실질적으로 무색의 순한 샴푸 조성물(mild, substantially coloriess shampoo compostion)
FR2697749B1 (fr)	1992-11-12	1995-01-13	Oreal	Composition cosmétique filmogène à base d'un copolymère chloré greffé résultant du greffage d'une polyoléfine chlorée et de monomères insaturés du type acrylique, styrénique et/ou vinylique.
DE4333893A1 (de)	1993-10-05	1995-04-06	Hoechst Ag	Kosmetische Zubereitungen
DE19518262A1 (de)	1995-05-18	1996-11-21	Hoechst Ag	Die Verwendung von Glyceryltriacetat zur Behandlung von Onychomykosen
US5424435A (en)	1993-10-18	1995-06-13	Olin Corporation	1-hydroxy-6-substituted-2-pyridones
DE4336434A1 (de)	1993-10-26	1995-04-27	Hoechst Ag	Pharmazeutische Zubereitung für die parenterale, enterale und dermale Verabreichung von praktisch unlöslichen Arzneistoffen und Verfahren zu ihrer Herstellung
CA2177683C (en)	1993-12-23	1999-12-28	George Endel Deckner	Tissue moisturizing and antimicrobial compositions
FR2718349B1 (fr)	1994-04-07	1996-05-31	Oreal	Compositions cosmétiques à appliquer sur l'ongle.
FR2719481B1 (fr) *	1994-05-05	1996-05-31	Oreal	Composition à base de composés antifongiques et de composés antibactériens halogènes pour diminuer la chute des cheveux.
FR2722689B1 (fr)	1994-07-20	1996-10-04	Fabre Pierre Dermo Cosmetique	Nouveau produit de combinaison comprenant un agent antifongique et du crotamiton comme potentialisateur de l'activite de l'agent antifongique, et compositions dermatologiques et/ou cosmetiques le comprenant
US5696164A (en)	1994-12-22	1997-12-09	Johnson & Johnson Consumer Products, Inc.	Antifungal treatment of nails
AT408067B (de)	1995-03-17	2001-08-27	Gebro Pharma Gmbh	Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
IL113057A (en)	1995-03-21	1999-01-26	Univ Ramot	Compositions for the treatment of dandruff
BR9904780A (pt)	1998-02-09	2000-03-08	Macrochem Corp	Esmalte fungicida para unhas e método de uso do mesmo
US6231875B1 (en)	1998-03-31	2001-05-15	Johnson & Johnson Consumer Companies, Inc.	Acidified composition for topical treatment of nail and skin conditions

1996
- 1996-09-27 DE DE19639817A patent/DE19639817A1/de not_active Withdrawn
1997
- 1997-09-16 US US09/077,191 patent/US6469033B1/en not_active Expired - Lifetime
- 1997-09-16 UA UA99042350A patent/UA56192C2/uk unknown
- 1997-09-16 RU RU99108754/14A patent/RU2203059C2/ru not_active IP Right Cessation
- 1997-09-16 YU YU13699A patent/YU49494B/sh unknown
- 1997-09-16 WO PCT/EP1997/005069 patent/WO1998013043A1/de not_active Ceased
- 1997-09-16 KR KR10-1999-7002622A patent/KR100457851B1/ko not_active Expired - Fee Related
- 1997-09-16 NZ NZ334848A patent/NZ334848A/xx not_active IP Right Cessation
- 1997-09-16 AT AT97910293T patent/ATE218862T1/de active
- 1997-09-16 HU HU9904317A patent/HU226911B1/hu not_active IP Right Cessation
- 1997-09-16 DE DE59707519T patent/DE59707519D1/de not_active Expired - Lifetime
- 1997-09-16 AU AU47745/97A patent/AU717333B2/en not_active Ceased
- 1997-09-16 ID IDW990128A patent/ID21948A/id unknown
- 1997-09-16 CA CA002267309A patent/CA2267309C/en not_active Expired - Fee Related
- 1997-09-16 IL IL12914497A patent/IL129144A0/xx not_active IP Right Cessation
- 1997-09-16 CN CNB971982651A patent/CN1141096C/zh not_active Expired - Fee Related
- 1997-09-16 EP EP97910293A patent/EP0928193B1/de not_active Expired - Lifetime
- 1997-09-16 PL PL97332579A patent/PL190298B1/pl not_active IP Right Cessation
- 1997-09-16 BR BR9712141-0A patent/BR9712141A/pt not_active Application Discontinuation
- 1997-09-16 CZ CZ19991074A patent/CZ290701B6/cs not_active IP Right Cessation
- 1997-09-16 TR TR1999/00661T patent/TR199900661T2/xx unknown
- 1997-09-16 PT PT97910293T patent/PT928193E/pt unknown
- 1997-09-16 ES ES97910293T patent/ES2178761T3/es not_active Expired - Lifetime
- 1997-09-16 JP JP51522298A patent/JP4203125B2/ja not_active Expired - Fee Related
- 1997-09-16 DK DK97910293T patent/DK0928193T3/da active
- 1997-09-25 TW TW086113945A patent/TW531418B/zh not_active IP Right Cessation
- 1997-09-25 AR ARP970104431A patent/AR008859A1/es not_active Application Discontinuation
- 1997-09-26 MY MYPI97004502A patent/MY117381A/en unknown
- 1997-09-26 ZA ZA9708639A patent/ZA978639B/xx unknown
- 1997-09-29 MA MA24813A patent/MA24332A1/fr unknown
1999
- 1999-03-17 BG BG103261A patent/BG64370B1/bg unknown
- 1999-03-25 NO NO19991459A patent/NO322072B1/no not_active IP Right Cessation
- 1999-03-26 OA OA9900070A patent/OA11027A/fr unknown

Also Published As

Publication number	Publication date
EP0928193A1 (de)	1999-07-14
OA11027A (fr)	2003-03-06
WO1998013043A1 (de)	1998-04-02
CA2267309C (en)	2006-02-21
UA56192C2 (uk)	2003-05-15
NO991459L (no)	1999-03-25
MY117381A (en)	2004-06-30
CZ107499A3 (cs)	1999-07-14
ATE218862T1 (de)	2002-06-15
DE19639817A1 (de)	1998-04-02
KR20000048674A (ko)	2000-07-25
PL332579A1 (en)	1999-09-27
BG103261A (en)	1999-09-30
TR199900661T2 (xx)	1999-06-21
CZ290701B6 (cs)	2002-09-11
US6469033B1 (en)	2002-10-22
HUP9904317A3 (en)	2001-07-30
YU49494B (sh)	2006-08-17
ID21948A (id)	1999-08-12
HK1022269A1 (en)	2000-08-04
IL129144A0 (en)	2000-02-17
CN1231610A (zh)	1999-10-13
NZ334848A (en)	2000-09-29
MA24332A1 (fr)	1998-04-01
AR008859A1 (es)	2000-02-23
NO322072B1 (no)	2006-08-07
DK0928193T3 (da)	2002-10-07
RU2203059C2 (ru)	2003-04-27
CA2267309A1 (en)	1998-04-02
YU13699A (sh)	1999-12-27
JP4203125B2 (ja)	2008-12-24
EP0928193B1 (de)	2002-06-12
AU4774597A (en)	1998-04-17
BR9712141A (pt)	1999-08-31
ES2178761T3 (es)	2003-01-01
TW531418B (en)	2003-05-11
PT928193E (pt)	2002-11-29
KR100457851B1 (ko)	2004-11-18
HU226911B1 (en)	2010-03-01
AU717333B2 (en)	2000-03-23
HUP9904317A2 (hu)	2000-05-28
NO991459D0 (no)	1999-03-25
CN1141096C (zh)	2004-03-10
JP2001501200A (ja)	2001-01-30
PL190298B1 (pl)	2005-11-30
DE59707519D1 (de)	2002-07-18
ZA978639B (en)	1998-03-27

Publication	Publication Date	Title
JP4203125B2 (ja)	2008-12-24	皮膚感染症の治療における１―ヒドロキシ―２―ピリドンの使用
JP7121954B2 (ja)	2022-08-19	抗細菌性薬剤併用物の組成物及び使用方法
Modak et al.	1988	Combined topical use of silver sulfadiazine and antibiotics as a possible solution to bacterial resistance in burn wounds
WO2001070213A2 (en)	2001-09-27	Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide oxy amide or 8-hydroxy quinoline structure
Ledoussal et al.	1992	Potent non-6-fluoro-substituted quinolone antibacterials: synthesis and biological activity
KR20150089086A (ko)	2015-08-04	박테리아 감염을 치료하기 위한 조성물 및 방법
WO2023246841A1 (en)	2023-12-28	Methods and uses of boron compounds in the treatment of nontuberculous mycobacterium infections and pharmaceutical compositions for treatment of same
CN105705147A (zh)	2016-06-22	新颖的噁唑烷酮抗菌化合物
Vogt et al.	1992	Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris
JP6525999B2 (ja)	2019-06-05	抗菌性組成物
KR20160115941A (ko)	2016-10-06	항세균제를 포함하는 제약학적 조합
JP2019116508A (ja)	2019-07-18	抗菌剤を含む医薬組成物
MXPA99002865A (en)	1999-09-01	Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
CN113262214A (zh)	2021-08-17	盐酸西那卡塞在制备抗菌药物中的应用
HK1022269B (en)	2004-08-20	Use of 1-hydroxy-2-pyridones in the manufacture of a medicament for treating skin infections
ZA200409944B (en)	2005-06-08	Polymorphic forms of phenyl oxazolidinone derivatives.
WO2025186334A8 (en)	2025-10-02	Lipidic alkynylcarbinols with anti-bacterial and anti-tuberculosis activity
Özden et al.	1986	Studies on the In Vitro Antibacterial Activities of mono,-di and-trisubstituted-2-phenylbcnzimidazoles-II
Sood et al.	2004	In vitro Intracellular Bactericidal Activity and In vivo Efficacy of RBx 8700 Against Slow Growing Mycobacteria